Elena Geuna

1.3k total citations
44 papers, 729 citations indexed

About

Elena Geuna is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Elena Geuna has authored 44 papers receiving a total of 729 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Elena Geuna's work include HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (10 papers) and Advanced Breast Cancer Therapies (7 papers). Elena Geuna is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (10 papers) and Advanced Breast Cancer Therapies (7 papers). Elena Geuna collaborates with scholars based in Italy, United Kingdom and United States. Elena Geuna's co-authors include Filippo Montemurro, Andrea Milani, Rossella Martinello, Caterina Aversa, Giorgio Valabrega, Massimo Aglietta, Johann S. de Bono, Danilo Galizia, Anna Sapino and Stefania Redana and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Elena Geuna

42 papers receiving 716 citations

Peers

Countries citing papers authored by Elena Geuna

Since Specialization

Citations

This map shows the geographic impact of Elena Geuna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Geuna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Geuna more than expected).

Fields of papers citing papers by Elena Geuna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Geuna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Geuna. The network helps show where Elena Geuna may publish in the future.

Co-authorship network of co-authors of Elena Geuna

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Geuna. A scholar is included among the top collaborators of Elena Geuna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Geuna. Elena Geuna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world 2025 ·ESMO Open ·Eva Blondeaux, (unknown), (unknown), (unknown), (unknown), Francesca Poggio, Alessandra Fabi, Grazia Arpino, (unknown), Elena Geuna, (unknown), (unknown), (unknown), Michelino De Laurentiis, (unknown), (unknown), Matteo Lambertini, Filippo Montemurro, Lucia Del Mastro	1
2	Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs) 2022 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Alberto Pisacane, Eliano Cascardi, Enrico Berrino, (unknown), Ivana Sarotto, Laura Casorzo, (unknown), Carla Boccaccio, Federica Verginelli, Silvia Benvenuti, Miriam Dellino, Paolo M. Comoglio, Filippo Montemurro, Elena Geuna, Caterina Marchiò, Anna Sapino	14
3	The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer 2021 ·Drug Design Development and Therapy ·(unknown), Vincenzo Guarini, Danilo Galizia, Elena Geuna, Filippo Montemurro	15
4	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition 2021 ·Nature Communications ·Federica Verginelli, Alberto Pisacane, Gennaro Gambardella, Antonio D’Ambrosio, (unknown), (unknown), (unknown), Laura Casorzo, Silvia Benvenuti, Eliano Cascardi, Rebecca Senetta, Elena Geuna, Andrea Ballabio, Filippo Montemurro, Anna Sapino, Paolo M. Comoglio, Carla Boccaccio	20
5	Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study 2020 ·ESMO Open ·Ornella Garrone, Andrea Michelotti, (unknown), Filippo Montemurro, Anna Maria Vandone, (unknown), Elena Geuna, (unknown), Claudia De Angelis, Cristiana Lo Nigro, (unknown), Nicola Crosetto, Massimo Di Maïo, Marco Merlano	12
6	Cancer of Unknown Primary ( CUP ): genetic evidence for a novel nosological entity? A case report 2020 ·EMBO Molecular Medicine ·Silvia Benvenuti, (unknown), Elena Geuna, Alberto Pisacane, Rebecca Senetta, Gennaro Gambardella, Giulia Maria Stella, Filippo Montemurro, Anna Sapino, Carla Boccaccio, Paolo M. Comoglio	7
7	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies 2017 ·Clinical Cancer Research ·Dejan Juric, Johann S. de Bono, Patricia LoRusso, John Nemunaitis, Elisabeth I. Heath, Eunice L. Kwak, T. Macarulla Mercadé, Elena Geuna, Maria J. de Miguel, Chirag Patel, Keisuke Kuida, Serap Sankoh, Eric H. Westin, Fabian Zohren, Yaping Shou, Josep Tabernero	76
8	Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt? 2017 ·Lung Cancer ·Marta Capelán, Desamparados Roda, Elena Geuna, Karim Rihawi, (unknown), Stan B. Kaye, Jaishree Bhosle, Udai Banerji, Mary O’Brien, Johann S. de Bono, Sanjay Popat, Timothy A. Yap	2
9	Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer 2016 ·Cancer Treatment Reviews ·Riccardo Ponzone, Fiorella Ruatta, Marco Gatti, Isabella Castellano, Elena Geuna, (unknown), Franziska Kubatzki, Paola Sgandurra, Anna Sapino, Filippo Montemurro	6
10	Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials 2015 ·Clinical Cancer Research ·Saeed Rafii, Desamparados Roda, Elena Geuna, Begoña Jiménez, Karim Rihawi, Marta Capelán, Timothy A. Yap, L. Rhoda Molife, Stanley B. Kaye, Johann S. de Bono, Udai Banerji	28
11	Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer 2015 ·Expert Opinion on Investigational Drugs ·Elena Geuna, Andrea Milani, Rossella Martinello, Caterina Aversa, Giorgio Valabrega, Maurizio Scaltriti, Filippo Montemurro	31
12	Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials 2015 ·British Journal of Cancer ·Elena Geuna, Desamparados Roda, Saeed Rafii, Begoña Jiménez, Marta Capelán, Karim Rihawi, Filippo Montemurro, Timothy A. Yap, S.B. Kaye, Johann S. de Bono, L. Rhoda Molife, Udai Banerji	27
13	The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials 2015 ·British Journal of Cancer ·Rajiv Kumar, Elena Geuna, Vasiliki Michalarea, Michela Guardascione, Ulrike Naumann, David Lorente, Stan B. Kaye, Johann S. de Bono	62
14	Metastatic breast cancer subtypes and central nervous system metastases 2014 ·The Breast ·Caterina Aversa, (unknown), Elena Geuna, Rossella Martinello, Andrea Milani, Stefania Redana, Giorgio Valabrega, Massimo Aglietta, Filippo Montemurro	94
15	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer 2012 ·Expert Opinion on Pharmacotherapy ·Filippo Montemurro, Valentina Rossi, Elena Geuna, Giorgio Valabrega, Rossella Martinello, Andrea Milani, Massimo Aglietta	7
16	Potential of afatinib in the treatment of patients with HER2-positive breast cancer 2012 ·Breast Cancer Targets and Therapy ·Giorgio Valabrega, Elena Geuna, Massimo Aglietta, Filippo Montemurro	14
17	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? 2011 ·Expert Opinion on Pharmacotherapy ·Elena Geuna, Andrea Milani, Stefania Redana, Valentina Rossi, Giorgio Valabrega, Massimo Aglietta, Filippo Montemurro	5
18	Early postoperative angiographic findings after carotid endarterectomy 1988 ·Acta Neurochirurgica ·(unknown), (unknown), (unknown), (unknown), (unknown), Elena Geuna	1
19	Course of intracranial pressure after extirpation of posterior fossa tumours 1984 ·Acta Neurochirurgica ·(unknown), (unknown), (unknown), (unknown), Elena Geuna	6
20	Multiple meningiomas 1983 ·Acta Neurochirurgica ·Elena Geuna, (unknown), (unknown), M Arrigoni	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact